Patient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival

This education will help clinicians develop evidence-based and collaborative treatment plans for the management of hormone-sensitive prostate cancer (HSPC) with ADT intensification, leading to improved outcomes, reduced risk of disease progression, and enhanced overall survival for individuals with HSPC.

Live Broadcast

1.00 available credits

Information

March 13, 2025

12:00 PM - 01:00 PM EDT

Virtual

ENROLL

Details

Presenters

Overview
Among patients diagnosed with prostate cancer, up to 40% are categorized as high-risk cases. Despite notable progress in treatment methods, there persists a considerable rate of disease recurrence. Within a span of ten years following radical prostatectomy, approximately 50% of patients encounter a recurrence, leading to a substantial risk of disease progression and mortality.
This educational activity will address the management of hormone-sensitive prostate cancer (HSPC) for the healthcare team, including risk assessment to effectively identify high-risk patients with HSPC who may benefit from intensification of androgen deprivation therapy (ADT). Expert thought leaders will present recent and emerging clinical data and challenging cases, and will additionally offer insights and advice regarding team-based treatment planning for HSPC based on their own real-world clinical practice experiences. The activity will enable clinicians to evaluate key clinical factors and make evidence-based treatment decisions that reduce the risk of disease progression. Keeping clinicians updated on the latest clinical trial results supporting ADT intensification in high-risk patients with HSPC is vital to patient outcomes. Analyzing and contextualizing the data and benefits demonstrated in recent trials will enable clinicians to make evidence-based and collaborative treatment decisions that optimize patient care.
Program Schedule*
- Introduction
- Which Patients Are Best Suited for Intensified ADT?
- Reviewing the Latest Evidence
- Patient-Centric ADT Intensification Planning
- Optimizing Team-Based Safety
- Practical Application: Case-Based Learning Lab
- Key Takeaways
- Question-and-Answer Session
- Post-Assessment Questions
*Subject to change
Disclosure of Relevant Financial Relationships
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: 
Mary-Ellen Taplin, MD has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Advisory board: Johnson & Johnson, GS, Astellas Pharma US, Inc., Amgen, Inc., AstraZeneca Pharmaceuticals LP, Blue Earth & Pfizer, Inc.
Advisor: Flare.
The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; and Adrienne N. Nedved, PharmD, MPA, BCOP hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Perform risk assessment for patients with HSPC to inform potential treatment planning involving ADT intensification
- Analyze and contextualize recent clinical trial evidence for ADT intensification in high-risk patients with HSPC
- Develop collaborative treatment plans for patients with HSPC that reduce risk for disease progression based on recent clinical trial evidence
- Incorporate an interprofessional, team-based approach to the implementation of adverse event management protocols in patients with HSPC receiving intensified ADT
Target Audience
This activity is designed to meet the educational needs of medical oncologists, urologists, pathologists, advanced practice clinicians, and other members of the interprofessional team who treat and manage prostate cancer in the academic setting.
Accreditation and Credit Designation Statements
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

CREDIT DESIGNATION FOR PHYSICIANS
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CREDIT DESIGNATION FOR PHYSICIAN ASSISTANTS
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 6/30/2025. PAs should only claim credit commensurate with the extent of their participation.
CREDIT DESIGNATION FOR PHARMACISTS
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-24-068-L01-P.
CREDIT DESIGNATION FOR NURSING
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour. Learners are advised that accreditedstatus does not imply endorsement by the provider or ANCC of anycommercial products displayed in conjunction with an activity.
CREDIT DESIGNATION FOR LABORATORY PROFESSIONALS
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education
Provider(s)/Educational Partner(s)
Commercial Support
This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no fee for this educational activity.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Mary-Ellen Taplin, MD

Details

Presenters

Recommended

Overview
Among patients diagnosed with prostate cancer, up to 40% are categorized as high-risk cases. Despite notable progress in treatment methods, there persists a considerable rate of disease recurrence. Within a span of ten years following radical prostatectomy, approximately 50% of patients encounter a recurrence, leading to a substantial risk of disease progression and mortality.
This educational activity will address the management of hormone-sensitive prostate cancer (HSPC) for the healthcare team, including risk assessment to effectively identify high-risk patients with HSPC who may benefit from intensification of androgen deprivation therapy (ADT). Expert thought leaders will present recent and emerging clinical data and challenging cases, and will additionally offer insights and advice regarding team-based treatment planning for HSPC based on their own real-world clinical practice experiences. The activity will enable clinicians to evaluate key clinical factors and make evidence-based treatment decisions that reduce the risk of disease progression. Keeping clinicians updated on the latest clinical trial results supporting ADT intensification in high-risk patients with HSPC is vital to patient outcomes. Analyzing and contextualizing the data and benefits demonstrated in recent trials will enable clinicians to make evidence-based and collaborative treatment decisions that optimize patient care.
Program Schedule*
- Introduction
- Which Patients Are Best Suited for Intensified ADT?
- Reviewing the Latest Evidence
- Patient-Centric ADT Intensification Planning
- Optimizing Team-Based Safety
- Practical Application: Case-Based Learning Lab
- Key Takeaways
- Question-and-Answer Session
- Post-Assessment Questions
*Subject to change
Disclosure of Relevant Financial Relationships
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: 
Mary-Ellen Taplin, MD has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Advisory board: Johnson & Johnson, GS, Astellas Pharma US, Inc., Amgen, Inc., AstraZeneca Pharmaceuticals LP, Blue Earth & Pfizer, Inc.
Advisor: Flare.
The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; and Adrienne N. Nedved, PharmD, MPA, BCOP hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Perform risk assessment for patients with HSPC to inform potential treatment planning involving ADT intensification
- Analyze and contextualize recent clinical trial evidence for ADT intensification in high-risk patients with HSPC
- Develop collaborative treatment plans for patients with HSPC that reduce risk for disease progression based on recent clinical trial evidence
- Incorporate an interprofessional, team-based approach to the implementation of adverse event management protocols in patients with HSPC receiving intensified ADT
Target Audience
This activity is designed to meet the educational needs of medical oncologists, urologists, pathologists, advanced practice clinicians, and other members of the interprofessional team who treat and manage prostate cancer in the academic setting.
Accreditation and Credit Designation Statements
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

CREDIT DESIGNATION FOR PHYSICIANS
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CREDIT DESIGNATION FOR PHYSICIAN ASSISTANTS
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 6/30/2025. PAs should only claim credit commensurate with the extent of their participation.
CREDIT DESIGNATION FOR PHARMACISTS
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-24-068-L01-P.
CREDIT DESIGNATION FOR NURSING
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour. Learners are advised that accreditedstatus does not imply endorsement by the provider or ANCC of anycommercial products displayed in conjunction with an activity.
CREDIT DESIGNATION FOR LABORATORY PROFESSIONALS
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education
Provider(s)/Educational Partner(s)
Commercial Support
This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no fee for this educational activity.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Mary-Ellen Taplin, MD

Patient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival

Program Schedule*

Disclosure of Relevant Financial Relationships

Learning Objectives

Target Audience

Accreditation and Credit Designation Statements

Provider(s)/Educational Partner(s)

Commercial Support

Disclaimer

System Requirements

Program Schedule*

Disclosure of Relevant Financial Relationships

Learning Objectives

Target Audience

Accreditation and Credit Designation Statements

Provider(s)/Educational Partner(s)

Commercial Support

Disclaimer

System Requirements

Recommended

Program Chapters

Segment Chapters

Playlist:

Recommended

Recommended

Title

Share on ReachMD

Program Chapters

Segment Chapters

Playlist:

Recommended

Get a Dose of ReachMD in Your Inbox and Practice Smarter Medicine